Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 11, 2016, Pages 2133-2135

  Varbo, Anette ^a,b   Nordestgaard, Børge G ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; LIPOPROTEIN;

ATHEROMA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE COURSE; EDITORIAL; HUMAN; INTRAVASCULAR ULTRASOUND; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROSIS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; LIPOPROTEINS; TRIGLYCERIDES;

EID: 84992740257     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308305     Document Type: Editorial

References (28)

1. Puri R, Nissen SE, Shao M, Elshazly MB, Kataoka Y, Kapadia SR, Tuzcu EM, Nicholls SJ. Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol. 2016; 36: 2220-2228. doi: 10.1161/ATVBAHA.116.307601.
2. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016; 118: 547-563. doi: 10.1161/CIRCRESAHA.115.306249.
3. Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, Quiney J, Lewis B. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991; 11: 569-577.
4. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intimainner media. Arterioscler Thromb Vasc Biol. 1995; 15: 534-542.
5. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384: 626-635. doi: 10.1016/S0140-6736(14)61177-6.
6. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61: 427-436. doi: 10.1016/j. jacc.2012.08.1026.
7. Borén J, Williams KJ. The central role of arterial retention of cholesterolrich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016; 27: 473-483. doi: 10.1097/MOL.0000000000000330.
8. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991; 11: 2-14.
9. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3: 213-219.
10. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298: 299-308. doi: 10.1001/ jama.298.3.299.
11. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008; 300: 2142-2152. doi: 10.1001/jama.2008.621.
12. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000.
13. Chapman MJ, Ginsberg HN, Amarenco P, et al; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32: 1345-1361. doi: 10.1093/eurheartj/ehr112.
14. Varbo A, Nordestgaard BG, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Benn M. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol. 2011; 69: 628-634. doi: 10.1002/ ana.22384.
15. Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem. 2015; 61: 533-543. doi: 10.1373/ clinchem.2014.234146.
16. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298: 309-316. doi: 10.1001/jama.298.3.309.
17. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45: 1345-1352. doi: 10.1038/ng.2795.
18. Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. Clin Chem. 2014; 60: 737-746. doi: 10.1373/ clinchem.2013.219881.
19. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016; 48: 634-639. doi: 10.1038/ng.3561.
20. Jepsen AM, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard BG. Increased remnant cholesterol explains part of residual risk of allcause mortality in 5414 patients with ischemic heart disease. Clin Chem. 2016; 62: 593-604. doi: 10.1373/clinchem.2015.253757.
21. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006; 367: 36-47. doi: 10.1016/j.cca.2005.12.013.
22. Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013; 128: 1298-1309. doi: 10.1161/CIRCULATIONAHA.113.003008.
23. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013; 34: 1826-1833. doi: 10.1093/eurheartj/ehs431.
24. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res. 2015; 116: 665-673. doi: 10.1161/ CIRCRESAHA.116.304846.
25. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010; 363: 692-694; author reply 694.
26. Landmark Trial Entitled "PROMINENT" To Explore The Prevention Of Heart Disease In Diabetic Patients With High Triglycerides And Low HDL-C. http: //www.pharmiweb.com/pressreleases/pressrel.asp?ROW- ID=146981. Accessed January 12, 2016.
27. Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol- fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 1988; 8: 421-428.
28. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res. 1988; 29: 1491-1500.